Immuneering Corp
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $128.6M+255.9% | $36.1M-39.2% | $59.4M-18.2% | $72.6M-3.0% | $74.9M |
| Marketable securities, current | $44.2M | $0 | — | $32.9M-55.7% | $74.3M |
| Prepaids and other current assets | $3.4M-0.8% | $3.4M+0.7% | $3.4M+6.5% | $3.2M+11.1% | $2.9M |
| Total current assets | $176.2M+345.2% | $39.6M-55.6% | $89.1M-18.1% | $108.7M-28.6% | $152.3M |
| Marketable securities, non-current | $44.2M | $0 | — | — | — |
| Property and equipment, net | $938K-16.4% | $1.1M-19.8% | $1.4M+2.3% | $1.4M+69.7% | $807K |
| Goodwill | $6.7M+0.0% | $6.7M+0.0% | $6.7M+0.0% | $6.7M-0.2% | $6.7M |
| Intangible asset, net | $321K-8.4% | $350K-7.7% | $380K-7.2% | $409K-6.8% | $439K |
| Right-of-use assets, net | $3.3M-9.4% | $3.7M-8.2% | $4.0M-9.3% | $4.4M-17.2% | $5.3M |
| Other assets | $284K-78.1% | $1.3M+25.3% | $1.0M+39.1% | $744K+628.2% | $102K |
| Total assets | $232.0M+340.1% | $52.7M-48.6% | $102.6M-16.2% | $122.4M-26.6% | $166.7M |
| Accounts payable | $1.5M-21.2% | $2.0M-7.3% | $2.1M-33.1% | $3.2M+126.2% | $1.4M |
| Accrued expenses | $7.8M+57.7% | $5.0M-3.9% | $5.2M+15.0% | $4.5M+13.5% | $4.0M |
| Other liabilities | $292K+24.8% | $234K-10.0% | $260K+1212.2% | $20K | — |
| Lease liabilities | $397K+17.3% | $338K+12.8% | $300K-20.8% | $379K+38.2% | $274K |
| Total current liabilities | $10.1M+34.2% | $7.5M-4.4% | $7.8M-2.6% | $8.1M+43.0% | $5.6M |
| Lease liabilities, net of current portion | $3.4M-10.4% | $3.8M-8.1% | $4.2M-6.7% | $4.5M-12.3% | $5.1M |
| Total liabilities | $13.5M+19.2% | $11.3M-5.7% | $12.0M-4.1% | $12.5M+16.7% | $10.7M |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued or outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | $0 | $0 | — |
| Additional paid-in capital | $498.7M+87.7% | $265.7M+4.7% | $253.8M+15.6% | $219.6M+2.0% | $215.3M |
| Accumulated other comprehensive income | $81K | $0+100.0% | -$778+97.4% | -$30K+38.5% | -$49K |
| Accumulated deficit | -$280.3M-25.0% | -$224.3M-37.4% | -$163.3M-48.7% | -$109.8M-85.2% | -$59.3M |
| Total stockholders' equity | $218.5M+427.9% | $41.4M-54.3% | $90.6M-17.5% | $109.9M-29.6% | $156.0M |
| Total liabilities and stockholders' equity | $232.0M+340.1% | $52.7M-48.6% | $102.6M-16.2% | $122.4M-26.6% | $166.7M |
| Class A Common Stock | |||||
| Common stock | $0 | $0 | $0-100.0% | $26K+0.4% | $26K |
| Class B Common Stock | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.